Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
SECTOR OVERVIEW Welcome to the first edition of the Pharma & Biotech Newsletter for 2021. To begin with let’s take a look at how the IIR Pharma & Biotech Index has begun the new year. The sector started the year fairly muted with the Index up just 0.5% in January. This was in line with the broader market, with the ASX All Ordinaries Accumulation Index up 0.3%. The top 10 constituents were a drag on the index, falling 2.1% in January. Imugene Limited (ASX: IMU) fell out of the top 10, with Starp...
A director at Noxopharm Limited sold 8,840,000 shares at 0.650AUD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Positive DARRT-1 Data in Late-Stage Prostate Cancer Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal (registration) DARRT-2/DARRT-3 study to commence 2020Combination NOX66 (Veyonda®) + palliative radiotherapy achieves durable anti-cancer response in high proportion of late-stage prostate cancer patients with no other standard treatment options10 of 15 patients (66%) scanned at 6-months had responded to treatment with stable disease or better ...
Noxopharm Announces Appointment of Chief Commercial Officer Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations in Australia and USAAppointment provides key commercial and financial strength to the company in a period of planned significant corporate growth SYDNEY, Australia, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX:NOX) is pleased to announce that it has appointed Mr Alexander Hunter as its Chief Commercial Officer. Mr Hunter has 15 ...
Potential for Fundamental Change in the Treatment of Brain Cancer Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international research showing key role of the brain chemical, glutamate, in driving aggressive growth of GBMNoxopharm owns what it believes to be world-leading technology in glutamate-inhibitionMajor opportunity to slow GBM growth and help preserve normal brain function SYDNEY, Australia, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX...
Veyonda® and Radiotherapy Profiled at Key Oncology Meeting Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts acceptedDARRT-1 interim data showing high incidence of a durable anti-cancer effect at 6 monthsRetrospective review by investigators showing Veyonda® significantly increasing the anti-cancer response to experimental radionuclide, 177lutetium-PSMA-617 SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ...
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results SYDNEY, Australia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on its proprietary treatment Veyonda® combined with radiotherapy which resulted in reductions in tumour size; reductions in pain for 45% of the men; and reductions in PSA levels for 55% of these men. The Company’s DARRT (Direct and Abscopal Respons...
Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now confirming this effectThis confirmation comes a week before release of key interim DARRT-1 clinical data SYDNEY, Australia, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to provide an update on results from a series of key proof-of-principle experiments in mice that are explori...
Appendix 4C– June 2019 Quarter Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery programBoard changes underpinning growthSuccessful fundraising completed in July intended to fund Company through to a proposed US Listing SYDNEY, Australia, July 29, 2019 (GLOBE NEWSWIRE) -- Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its Appendix 4C for the quarter ended 30 June 2019, as well as providing guidance for the next 12...
Noxopharm Announces AU$26 Million Funding Facility KEY HIGHLIGHTS AU$4,000,000 initial fundingEquity placement component of up to additional AU$22,000,000 in ordinary shares over 12 monthsFlexible funding package leading up to a proposed U.S. Listing SYDNEY, Australia, July 19, 2019 (GLOBE NEWSWIRE) -- Noxopharm Ltd (‘Noxopharm’ or the ‘Company’) (ASX:NOX) in recent months has released interim clinical data from both its DARRT-1 and LuPIN studies with both showing encouraging evidence that its immuno-oncology drug candidate, Veyonda®, is providing meaningful anti-...
Conference Hears of Positive Interim Data from LuPIN Trial KEY HIGHLIGHTS LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC) Clinical data shows combining Veyonda® with radiopharmaceutical, 177Lu-PSMA-617, is well tolerated and with early signals of anti-cancer activityOverall 69% PSA response rate (>50% reduction in PSA levels) with 177Lu-PSMA-617 + Veyonda® SYDNEY, Australia, June 26, 2019 (GLOBE NEWSWIRE) -- Noxopharm Ltd (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to report on positive interim clinical data from the ongoing LuP...
Promising Data Leads to Expansion of LuPIN Trial LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda® 1200 mgThe objective is to see whether the dose-response effect seen to date will lead to even greater response ratesData from total of 56 patients expected to lay foundation for pivotal registration trial. SYDNEY, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) in collaboration with St Vincent’s Hospital, Sydney, are pleased to announce that the LuPIN trial, which is investigating 177Lu-PSMA-617 in ...
LuPIN Trial Demonstrates High Rates of Response Data published today describes positive interim results from the LuPIN trial Veyondaâ (NOX66) dose-finding study69% combined PSA response rate is higher than that observed in studies of 177Lu-PSMA-617 alone75% of men treated with Veyondaâ 800 mg and 177Lu-PSMA-617 achieved a PSA response. SYDNEY, Australia, May 20, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to announce that A/Professor Louise Emmett will deliver an oral presentation of interim results from the LuPIN trial at the Society of Nuclea...
DARRT Treatment Has Lasting Disease Control at Six Months Long-lasting responses with Veyonda® + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatmentComplete resolution of pain achieved in some patients SYDNEY, Australia, May 02, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to announce the 6-month interim results from the dose-escalation arm of the DARRT-1 (Direct and Abscopal Response to Radio‐Therapy) study. The Company previously (6 Feb 2019) reported on the int...
Idronoxil Confirmed as Noxopharm’s New Immuno-Oncology Drug Candidate New class of immuno-oncology drug identifiedActivator of NK cells and CD4+ immune cellsPotential to boost function of current immuno-oncology drugs. SYDNEY, Australia, April 16, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) releases data from the first series of pre-clinical studies confirming that idronoxil (IDX), the active ingredient in the Company’s anti-cancer drug candidate, Veyonda®, activates the immune system. The studies confirm that IDX activates cells associated with both the innate and adaptive immune syst...
Veyonda® Chemotherapy Enhancement Program to be Expanded Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancersU.S. study to investigate Veyonda® + doxorubicin in sarcomasCEP-2 target start Q4 2019Comprehensive plan on track to establish Veyonda® as key, versatile cancer drug SYDNEY, Australia, April 10, 2019 (GLOBE NEWSWIRE) -- Noxopharm Ltd (ASX: NOX) (Noxopharm or the ‘Company’) provides an update on the progress of its Veyonda® chemotherapy enhancement program (CEP) which is being run in parallel to the Company’s two radio-...
Combination of Veyonda® + Radiotherapy Delivers Clinical Benefits In Noxopharm’s DARRT-1 Interim Results Interim (12-week) DARRT-1 readout Combination Veyonda® + low-dose radiotherapy well toleratedPSA, pain and tumour responses at higher doses24-week readout to indicate longevity of response. SYDNEY, Australia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) announces interim (12-week) results from the dose-ranging component of the DARRT-1 study. 1. Key findings: combining Veyonda® with low-dose radiotherapy applied to a single metastasis (lesion) is able to produce an anti-can...
Principal Investigator Discusses LuPIN-1 Study Lu-PIN-1 Study two-thirds enrolledStudy testing ability of Veyonda® to boost effect of Novartis experimental drugNoxopharm to initiate LuPIN-2 study. SYDNEY, Australia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Noxopharm (NOX: ASX) today releases an interview with Associate Professor Louise Emmett, the co-Principal Investigator of the LuPIN-1 Study being conducted at St Vincent’s Hospital, Sydney. LuPIN-1 is being conducted in men with late-state prostate cancer and involves combination therapy of Veyonda® and an experimental radiopharmaceutical dr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.